Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - TG THERAPEUTICS, INC. | v120616_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - TG THERAPEUTICS, INC. | v120616_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
_____________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of report
(Date of earliest event reported): December 6, 2016
TG Therapeutics, Inc.
(Exact Name of
Registrant as Specified in Charter)
|
Delaware
(State or Other
Jurisdiction
of
Incorporation)
|
001-32639
(Commission File
Number)
|
36-3898269
(IRS Employer
Identification No.)
|
2 Gansevoort Street, 9th
Floor
New York, New York 10014
(Address of
Principal Executive Offices)
(212) 554-4484
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425
under the Securities Act.
|
|
☐
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act.
|
|
☐
|
Pre-commencement communications pursuant to Rule
14d-2b under the Exchange Act.
|
|
☐
|
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act.
|
Item 8.01. Other Events.
On December 6,
2016, TG Therapeutics, Inc. issued press releases announcing
presented data from three combination studies involving the
Company’s lead compounds, TGR-1202 and TG-1101 (ublituximab)
in combination with other compounds, at the 58th American Society
of Hematology (ASH) Annual Meeting, being held in San Diego, CA. A
copy of the press release is being filed as Exhibit 99.1 and
incorporated in this Item by reference. In addition, on December 6,
2016 the Company also issued a press releasing announcing that the
target enrollment for the GENUINE Phase 3 study has been met and
enrollment will be closed shortly. A copy of the press release is
being filed as Exhibit 99.2 and incorporated in this Item by
reference.
Item 9.01 Financial Statements And
Exhibits.
(d)
Exhibits.
99.1 Press
Release, dated December 6, 2016.
99.2 Press
Release, dated December 6, 2016.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
TG Therapeutics, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
Date: December 6,
2016
|
|
|
|
By: /s/
Sean A.
Power
|
|
|
Sean A.
Power
|
|
|
Chief Financial
Officer
|
|
|
|
INDEX
TO EXHIBITS
|
|
|
|
|
Exhibit
|
|
|
|
Number
|
|
Description
|
|
|
|
|
|
99.1.
|
|
Press Release,
dated December 6, 2016.
|
|
|
|
|
|
99.2
|
|
Press Release,
dated December 6, 2016.
|
|
|
|
|